No results for ‘’
Alembic Pharmaceuticals Ltd
NSE: APLLTD BSE: 533573
₹844.25
(0.53%)
Sun, 27 Sept 2026, 07:45 pm
Market Cap (in Cr)16714.74
PE Ratio23.93
Dividend1.42
Health Technology
Pharmaceuticals: Major
24.5KAlembic Pharmaceuticals Cashflow
| Particulars | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deprecation and amortization | -430.20M | -295.92M | -336.50M | -349.69M | -404.87M | -444.13M | -722.10M | -829.70M | -1.05B | -1.15B | -1.57B | -1.83B | -2.87B | -2.75B | -2.73B | -2.79B |
| Accumulated depreciation, total | — | -1.62B | -1.95B | -2.28B | -2.68B | -3.14B | -3.86B | -1.51B | -2.46B | -3.51B | -4.95B | -6.63B | -8.59B | -10.69B | -13.28B | -15.94B |
| Cash from operating activities | — | 743.00M | 1.08B | 2.54B | 2.26B | 1.69B | 9.45B | 3.25B | 2.88B | 7.46B | 3.40B | 13.92B | 5.05B | 6.75B | 7.57B | 148.70M |
| Funds from operations | — | 1.23B | 1.44B | 2.11B | 2.98B | 3.31B | 8.06B | 4.90B | 4.69B | 6.38B | 9.33B | 11.54B | 8.72B | 7.33B | 8.53B | 9.36B |
| Net income (cash flow) | 395.40M | 853.88M | 1.30B | 1.65B | 2.36B | 2.83B | 7.20B | 4.03B | 4.13B | 5.84B | 8.29B | 11.46B | 5.21B | 3.42B | 6.16B | 5.83B |
| Depreciation & amortization (cash flow) | — | 295.92M | 336.50M | 349.69M | 404.87M | 444.13M | 722.10M | 829.70M | 1.05B | 1.15B | 1.57B | 1.83B | 2.87B | 2.75B | 2.73B | 2.79B |
| Depreciation/depletion | — | 295.92M | 336.46M | 349.65M | 404.87M | 444.13M | 722.10M | 829.70M | 1.02B | 1.06B | 1.44B | 1.69B | 1.98B | 2.19B | 2.73B | 2.79B |
| Amortization | — | 0 | 40.00K | 33.00K | 0 | 0 | 0 | 0 | 35.40M | 90.80M | 135.80M | 148.10M | 888.60M | 563.80M | 0 | — |
| Deferred taxes (cash flow) | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-cash items | — | -132.50M | -502.47M | -298.93M | -529.98M | -721.20M | -2.03B | -1.22B | -1.78B | -2.27B | -2.24B | -3.98B | -397.70M | 1.03B | -513.90M | -495.40M |
| Changes in working capital | — | -488.84M | -362.95M | 429.93M | -720.72M | -1.63B | 1.39B | -1.66B | -1.81B | 1.09B | -5.93B | 2.38B | -3.67B | -575.70M | -956.50M | -9.21B |
| Cash from investing activities | — | -623.52M | -609.46M | -854.24M | -818.61M | -2.58B | -3.09B | -4.87B | -8.86B | -7.60B | -7.33B | -8.40B | -3.77B | -4.49B | -3.24B | -5.74B |
| Capital expenditures | — | -625.38M | -612.56M | -859.73M | -819.63M | -2.24B | -3.01B | -5.10B | -8.22B | -7.64B | -7.35B | -6.60B | -4.26B | -4.43B | -3.27B | -5.64B |
| Capital expenditures - fixed assets | — | -625.38M | -612.56M | -859.73M | -819.63M | -2.24B | -3.01B | -5.10B | -7.49B | -6.54B | -7.35B | -6.60B | -4.26B | -4.43B | -3.27B | -5.64B |
| Capital expenditures - other assets | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -723.90M | -1.10B | 0 | — | — | — | — | — |
| Cash from financing activities | — | -207.22M | -63.54M | -2.00B | -1.40B | 917.20M | -2.11B | -1.29B | 5.28B | 1.30B | 2.66B | -5.24B | -1.65B | -2.14B | -3.88B | 5.22B |
| Free cash flow | — | 117.62M | 468.34M | 1.68B | 1.44B | -547.20M | 6.44B | -1.86B | -4.62B | 923.90M | -3.95B | 7.33B | 794.00M | 2.32B | 4.30B | -5.49B |